Deep-Tech Commercialization Readiness

Know what weak and strong look like

Build a risk-retirement matrix

List technical, manufacturing, regulatory, customer, procurement, supply, unit-cost and financing risks. For each, define current evidence, next experiment/deal, pass criterion, cost, time and financing source.

Quantify the customer’s adoption problem

A 30% technical improvement may not matter if switching requires a 24-month validation, plant shutdown or new certification. Interview users, technical evaluators, procurement, finance and the economic buyer—not just innovation teams.

Separate technology readiness from adoption readiness

A technically mature solution can be commercially immature if integration, infrastructure, workforce, policy, permitting, market structure or financing is unresolved. Track both tracks explicitly.

Design milestones investors can underwrite

Replace “complete R&D” with evidence such as third-party validation at target operating conditions, paid pilot with success criteria, regulatory submission, signed offtake/MOU with economic terms, or verified unit-cost curve at pilot scale.

Match capital to the risk

Use nondilutive research funding where appropriate for technical uncertainty, customer/strategic capital for validation, equity for company-building risk, and project/asset finance only when cash flows and counterparties can support it. Do not burn expensive equity solving a risk that another capital source is designed to fund.

Run the diligence stress test before investors do

Do not rehearse an answer. Rehearse the evidence. Give yourself a short diligence window and try to produce the underlying records without rebuilding the story from memory. A clean result is reproducible, tied to a source system or signed document, and consistent with the numbers elsewhere in the company.

• Technical proof: Put the underlying records on screen and prove this standard: Performance claims have protocol, baseline, sample size, repeatability and third-party evidence where material. If the evidence still looks like this weak state—Best lab result shown without test conditions or repeatability.—record the gap, name an owner and give it a due date instead of explaining it away.
• Customer proof: Put the underlying records on screen and prove this standard: Named use case, buyer, adoption barrier, budget path and quantified value hypothesis tested. If the evidence still looks like this weak state—Letters of “interest” substitute for workflow/economic discovery.—record the gap, name an owner and give it a due date instead of explaining it away.
• Regulatory/procurement: Put the underlying records on screen and prove this standard: Gates, standards, approvals, procurement lead time and decision owners mapped. If the evidence still looks like this weak state—Treated as paperwork after product completion.—record the gap, name an owner and give it a due date instead of explaining it away.
• Partners: Put the underlying records on screen and prove this standard: Partner contribution, dependency, economics, obligations and next decision milestone documented. If the evidence still looks like this weak state—Logos on slide with no role.—record the gap, name an owner and give it a due date instead of explaining it away.
• Capital: Put the underlying records on screen and prove this standard: Grant, strategic, project/debt and equity capital matched to risk type and asset stage. If the evidence still looks like this weak state—VC expected to fund every development phase.—record the gap, name an owner and give it a due date instead of explaining it away.

Do the math investors will do

Commercialization scorecard: each major risk gets 0 = hypothesis, 1 = internal evidence, 2 = external/partner evidence, 3 = repeatable commercial evidence. The company does not become “ready” because the average score rises; the gating risk matters. A single unresolved regulatory or manufacturing gate can dominate ten well-developed customer interviews.

Build the evidence investors can verify

• Technical validation dossier
• Customer-discovery interview map with buying/adoption evidence
• Risk-retirement matrix
• Regulatory/standards/procurement map
• Partner dependency and economics matrix
• Milestone-based 24-month plan
• Capital-stack map tied to specific risks

Questions an investor may ask

• What must be true for a customer to adopt at commercial scale?
• Which result has been independently validated?
• What is the current gating risk—not the most exciting risk?
• Which milestones unlock a different class of capital?
• What partner can stop the commercialization path if it withdraws?

30-day repair sprint

• Days 1–5: inventory all technical and adoption risks.
• Days 6–10: score current evidence and identify the gating three.
• Days 11–15: map buyer/procurement/regulatory path.
• Days 16–20: rewrite milestones as pass/fail evidence.
• Days 21–25: match capital source to each milestone.
• Days 26–30: produce one integrated commercialization roadmap and kill claims not supported by evidence.